Skip to main content
Clinical Trials/NCT03383081
NCT03383081
Recruiting
Phase 2

A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis

Sclnow Biotechnology Co., Ltd.1 site in 1 country60 target enrollmentOctober 1, 2018

Overview

Phase
Phase 2
Intervention
Low dose mesenchymal stem cells
Conditions
Osteoarthritis, Knee
Sponsor
Sclnow Biotechnology Co., Ltd.
Enrollment
60
Locations
1
Primary Endpoint
Kellgren-Lawrence Grading Scale
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease

Detailed Description

This is a random, open label, and parallel controled experiment. All patients are selected and sign consent forms, then divided into 3 groups. Doctors collect the basic information of patient. All patients receive laboratory and image examination as baseline. Then, they will give cell treatment based on the clinical protocol. Doctors have follow-up visit on 2 weeks, 1, 2, 3, 6, and 12 months after treatment, and do safety and efficacy evaluation. Safety evaluation. Researcher collect all examination data of patients and compare with each groups. The safety tests including blood routine, urine routine, hepatorenal function, C reactive protein, erythrocyte sedimentation rate, and tumor marker, etc. Efficacy evaluation. Based on Lysholm, the international knee documentation committee (IKDC) knee evaluation form, and Visual Analogue Scale/Score (VAS) to examine the change/improvement of knee joint function. By Magnetic Resonance Imaging (MRI) examination, grade patients with Kellgren-Lawrence Grading Scale, Assessment of Preoperative Cartilage Defect Severity (AMADEUS), and observe the change/improvement of patient.

Registry
clinicaltrials.gov
Start Date
October 1, 2018
End Date
December 31, 2026
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sclnow Biotechnology Co., Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Knee Osteoarthritis by Kellgren and Lawrence Grading Scale, classified with Grade 2-3
  • Confirm with cartilage injury,articular cartilage part or full-thickness injury, by MR (Magnetic Resonance)
  • Age \<70, no serious organ dysfunction
  • Over 2 years knee pain or no very effective with conservative treatments
  • Knee pain of VAS (visual analog scale score) is 4 or higher
  • Normal hepatic and renal function, no history of gout, rheumatoid arthritis, and autoimmune diseases, etc.
  • Understand and sign the consent form of this study

Exclusion Criteria

  • Refuse to sign the consent form, or cannot keep follow-up visit
  • Age \>70; Age \<70, but with multiple organ failure
  • Unstable vital signs (breath, blood pressure, pulse)
  • Combined with knee ligament (anterior and the posterior cruciate ligament, medial and lateral collateral ligament) rupture, laxity, etc.
  • Serious bleeding tendency, poor coagulation function (PTA \<35%)
  • Pregnant or breast feeding women, or positive pregnancy test in 7 days before treatment
  • Participate other clinical experiments in 3 months
  • With progressing malignant tumor
  • Combined with shock and critically ill patients
  • With mental disease, cannot

Arms & Interventions

Low dose mesenchymal stem cells

Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)

Intervention: Low dose mesenchymal stem cells

Low dose mesenchymal stem cells

Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)

Intervention: Intraarticular injection

High dose mesenchymal stem cells

High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)

Intervention: High dose mesenchymal stem cells

High dose mesenchymal stem cells

High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)

Intervention: Intraarticular injection

Outcomes

Primary Outcomes

Kellgren-Lawrence Grading Scale

Time Frame: 12 months

Using Magnetic Resonance Imaging (MRI) examination, and based on the images of bilateral knee joint, grade by Kellgren-Lawrence Grading Scale. Kellgren-Lawrence Grading Scale is a method of classifying the severity of knee osteoarthritis (OA). Grade 0: No radiographic features of osteoarthritis; Grade 1: Possible joint space narrowing (normal joint space is at least 2 mm at the superior acetabulum) and osteophyte formation; Grade 2: Definite osteophyte formation with possible joint space narrowing; Grade 3: Multiple osteophytes, definite joint space narrowing, sclerosis and possible bony deformity; Grade 4: Large osteophytes, marked joint space narrowing, severe sclerosis and definite bony deformity.

Secondary Outcomes

  • Lysholm scoring(12 months)
  • Assessment of Preoperative Cartilage Defect Severity (AMADEUS)(12 months)
  • Visual Analogue Scale/Score(VAS)(12 months)
  • The international knee documentation committee (IKDC) knee evaluation form(12 months)

Study Sites (1)

Loading locations...

Similar Trials